Alper Topal, MD
@dralpertopal
Followers
467
Following
11K
Media
31
Statuses
581
Medical Oncology #precisionmedicine #immunooncology #immunotherapy #Lungcancer #BreastCancer #GUcancers
Ankara, Türkiye
Joined March 2020
In a study published in NEJM involving more than 1700 patients with cancer-related VTE, reduced-dose apixaban (2.5 mg twice daily) resulted in similar 12-month VTE recurrence rates compared with full-dose (5 mg twice daily) apixaban (2.1 versus 2.8 per cent). However, fewer
4
52
211
RT @matteolambe: Grateful to @ASCO for the opportunity to contribute to #ASCODailyNews with super @Lucarecco discussing how to choose betwe….
dailynews.ascopubs.org
Updates from the monarchE and NATALEE trials have reshaped the therapeutic landscape for patients with ER-positive, HER2-negative early-stage breast cancer, giving CDK4/6 inhibitors a prominent new...
0
13
0
RT @Erman_Akkus: 📗Gastric cancer with synchronous peritoneal metastases.Consensus guideline @JournalCancer . 👉 #can….
0
27
0
📢 AIM-HIGH work ❗️❗️❗️.🔹 Multinational, phase 3, randomised trial. 🔹 236 patients with stage IA-IIA non-squamous NSCLC were included. 🔹 Patients with molecular high risk (high/intermediate score) detected by 14-gene profiling were assigned 1:1 to adjuvant platinum-based KT or
0
4
13
RT @JAMAOnc: Viewpoint: Cabozantinib capsules are more cost-effective than tablets for treating various cancers, and adopting capsule-based….
0
20
0
RT @JAMAOnc: Induction-concurrent chemotherapy does not significantly improve progression-free survival compared with concurrent-adjuvant c���.
0
21
0
RT @to_be_elizabeth: 📌 Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights✨. .
0
46
0
RT @myESMO: 📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options appr….
0
17
0
RT @PTarantinoMD: T-DXd has shown tremendous activity in trials. But how does it perform in the real world? What is its activity in pts wit….
0
69
0
💉 Revolution in Cancer Vaccines Has Begun ‼️.🔬 Vaccines are now a powerful weapon not only against infections but also in the fight against cancer!. 🧠 New generation ‘cancer vaccines’ target tumours and train the immune system. ✅ Personalised vaccines can be produced with
1
3
7
An interesting and nice article published in @JAMANetworkOpen. 📌real world data in patients with advanced #NSCLC after platin+ IO. Ⓜ️ PFS: 5.3 months.Ⓜ️ OS: 11.2 months.➡️ Most common index regimen: Docetaxel ± ramucirumab.➡️ 131 different regimens used.️↪️IO rechallange in
1
4
15
RT @OscarTahuahua: Advances in Molecular Pathology & Therapy of NSCLC . 🌟Precision oncology is no longer optional. This review maps the mol….
0
51
0
0
424
0
